1
|
Gerdes S, Staubach P, Dirschka T, Wetzel D, Weirich O, Niesmann J, da Mota R, Rothhaar A, Ardabili M, Vlasitz G, Feldwisch J, Osterling Koskinen L, Ohlman S, Peloso PM, Brun NC, Frejd FY. Izokibep for the treatment of moderate-to-severe plaque psoriasis: a phase II, randomized, placebo-controlled, double-blind, dose-finding multicentre study including long-term treatment. Br J Dermatol 2023; 189:381-391. [PMID: 37697683 DOI: 10.1093/bjd/ljad186] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2022] [Revised: 05/26/2023] [Accepted: 05/29/2023] [Indexed: 09/13/2023]
Abstract
BACKGROUND Monoclonal antibodies to interleukin (IL)-17 have shown strong efficacy in patients with psoriasis. Izokibep is a unique IL-17A inhibitor with a small molecular size and favourable distribution to sites of inflammation. OBJECTIVES To evaluate the dose response, efficacy and safety of izokibep in patients with plaque psoriasis. METHODS In this double-blind, randomized, phase II dose-finding study (AFFIRM-35) in adults with moderate-to-severe plaque psoriasis and inadequate response to two or more standard therapies, patients were randomized (1:1:1:1:1) to placebo or izokibep 2, 20, 80 or 160 mg every 2 weeks for 12 weeks. During the remainder of the 52-week core study, patients given placebo were switched to izokibep 80 mg, and dosing intervals were adapted based on Psoriasis Area and Severity Index (PASI) scores for all patients. The core study was followed by two optional consecutive 1-year extension periods for a total duration of 3 years. The primary endpoint was a 90% reduction in PASI score (PASI 90) at week 12. Additional efficacy outcomes and adverse event (AE) rates were evaluated. RESULTS In total, 109 patients were randomized [safety set, n = 108 (one exclusion criteria failure); full analysis set, n = 106]. At week 12, PASI 90 response rates were 0%, 5%, 19%, 71% and 59% for the placebo, 2-, 20-, 80- and 160-mg izokibep groups, respectively. Rapid dose-dependent improvements were also observed across other efficacy outcomes. During the placebo-controlled period, AEs in the izokibep groups were similar to placebo except for mild injection site reactions. AEs were generally mild to moderate and the drug was well tolerated. Izokibep maintained efficacy at the higher dosage groups for up to 3 years, with no new safety signals. CONCLUSIONS Data from this phase II study indicate that izokibep is well tolerated and efficacious in the treatment of plaque psoriasis. Higher doses or more frequent dosing could be explored to further enhance response rates.
Collapse
Affiliation(s)
- Sascha Gerdes
- Psoriasis Center, Department of Dermatology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
| | - Petra Staubach
- Department of Dermatology, Medical Center, Medical University Center, Mainz, Germany
| | - Thomas Dirschka
- Germany Private Practice for Dermatology, Wuppertal, Germany
| | | | | | | | - Rodrigo da Mota
- Private Practice Dr. Hilton & Partner for Dermatology, Düsseldorf, Germany
| | | | | | | | | | | | | | | | | | - Fredrik Y Frejd
- Affibody AB, Solna, Sweden
- Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden
| |
Collapse
|
2
|
Liu Y, Sorensen JB, Brun NC, Frejd FY, Tolmachev V. Theranostic pairing: ABY-025/251 targeting HER2 with 68Ga and 188Re—Minimized radioligands using Affibody peptide scaffold technology. J Clin Oncol 2022. [DOI: 10.1200/jco.2022.40.16_suppl.3093] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
3093 Background: HER2 expressing tumors such as subsets of metastatic breast cancer and gastro-esophageal tumors can be targeted using specific antibodies or antibody-drug-conjugates (ADCs). However, some tumors remain refractory to treatment. External radiation therapy is unsuited to advanced metastatic disease. Targeted molecular radiation therapy has proven useful in other tumors such as neuroendocrine tumors or prostate cancer using 177Lu. 188Re is a beta emitting isotope that when chelated to the ABY-251 Affibody molecule has the potential to precisely target HER2 expressing tumors locally. The ABY-251 Affibody molecule is a very small, structured protein scaffold with a molecular weight of only 7 kDa targeting HER2 with high affinity (KD = 100pM). ABY-251 can be manufactured by chemical synthesis. A diagnostic analog molecule ABY-025 was also developed with chelation to 68Ga ideal for PET visualization. Methods: A pre-clinical study in mice was conducted to investigate tumor/tissue uptake, followed by a clinical diagnostic study for visualization in HER+ patients with metastatic breast cancer, to be followed by a theranostic study in humans. Results: Pre-clinical Study: A preclinical study in mice has previously demonstrated high contrast uptake in HER2 tumor tissue using the diagnostic analog ABY-025. Off target accumulation was seen in kidney tissue using the diagnostic ABY-025, which in the ABY-251 therapeutic molecule has been reduced by further engineering of the molecule. This molecule has now been proven to increase survival in mice bearing HER2+ tumors. Median survival in the treated animals was 68 days as compared to 29 and 27.5 days in animals treated with vehicle and non-labelled peptide respectively. Clinical diagnostic study ph1/2: ABY-025 was studied in HER2+ patients with metastatic breast cancer. In a study of 16 women with refractory metastatic breast cancer (>2 prior lines of therapy, 12 IHC positive and 4 IHC negative) 9 out of 10 patients showed high HER2 expression levels as measured with ABY-025 PET despite ongoing treatment with HER2 targeted therapy. Persistent high 68Ga-ABY-025 tumor uptake in patients despite treatment with standard HER2-targeted therapies is a sign of therapeutic drug resistance. These patients would be eligible for treatment with the therapeutic analog ABY-251 using 188Re generated beta radiation for tumor eradication. Clinical therapeutic study (planned): ABY-251 is in development to soon enter therapeutic clinical Ph1/2a trials in patients with refractory HER2+ tumors and positive tumor imaging using ABY-025 as a theranostic pair. Conclusions: A radiopharmaceutical theranostic approach diagnosing HER2+ patients with metastatic disease using 68Ga-ABY-025 for targetability and subsequent treatment using 188Re-ABY-251 seems feasible and is currently in clinical trials. Clinical trial information: NCT01858116.
Collapse
Affiliation(s)
| | | | | | | | - Vladimir Tolmachev
- Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden
| |
Collapse
|
3
|
Pottegård A, Kristensen KB, Reilev M, Lund LC, Ernst MT, Hallas J, Thomsen RW, Christiansen CF, Sørensen HT, Johansen NB, Støvring H, Christensen S, Kragh Thomsen M, Husby A, Voldstedlund M, Kjær J, Brun NC. Existing Data Sources in Clinical Epidemiology: The Danish COVID-19 Cohort. Clin Epidemiol 2020; 12:875-881. [PMID: 32848476 PMCID: PMC7429185 DOI: 10.2147/clep.s257519] [Citation(s) in RCA: 23] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2020] [Accepted: 07/10/2020] [Indexed: 12/18/2022] Open
Abstract
Background To facilitate research on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a prospective cohort of all Danish residents tested for SARS-CoV-2 in Denmark is established. Data Structure All Danish residents tested by reverse transcriptase polymerase chain reactions (RT-PCR) for SARS-CoV-2 in Denmark are included. The cohort is identified using the Danish Microbiology Database. Individual-level record linkage between administrative and health-care registries is facilitated by the Danish Civil Registration System. Information on outcomes related to SARS-CoV-2 infection includes hospital admission, intensive care unit admission, mechanical ventilation, and death and is retrieved from the five administrative Danish regions, the Danish National Patient Registry, and the Danish Register of Causes of Death. The Patient Registry further provides a complete hospital contact history of somatic and psychiatric conditions and procedures. Data on all prescriptions filled at community pharmacies are available from the Danish National Prescription Registry. Health-care authorization status is obtained from the Danish Register of Healthcare Professionals. Finally, selected laboratory values are obtained from the Register of Laboratory Results for Research. The cohort is governed by a steering committee with representatives from the Danish Medicines Agency, Statens Serum Institut, the Danish Health Authority, the Danish Health Data Authority, Danish Patients, the Faculties of Health Sciences at the Danish universities, and Danish regions. The steering committee welcomes suggestions for research studies and collaborations. Research proposals will be prioritized based on timeliness and potential clinical and public health implications. All research protocols assessing specific hypotheses for medicines will be made publicly available using the European Union electronic Register of Post-Authorisation Studies. Conclusion The Danish COVID-19 cohort includes all Danish residents with an RT-PCR test for SARS-CoV-2. Through individual-level linkage with existing Danish health and administrative registries, this is a valuable data source for epidemiological research on SARS-CoV-2.
Collapse
Affiliation(s)
- Anton Pottegård
- Clinical Pharmacology and Pharmacy, Department of Public Health, University of Southern Denmark, Odense, Denmark
| | - Kasper Bruun Kristensen
- Clinical Pharmacology and Pharmacy, Department of Public Health, University of Southern Denmark, Odense, Denmark
| | - Mette Reilev
- Clinical Pharmacology and Pharmacy, Department of Public Health, University of Southern Denmark, Odense, Denmark
| | - Lars Christian Lund
- Clinical Pharmacology and Pharmacy, Department of Public Health, University of Southern Denmark, Odense, Denmark
| | - Martin Thomsen Ernst
- Clinical Pharmacology and Pharmacy, Department of Public Health, University of Southern Denmark, Odense, Denmark
| | - Jesper Hallas
- Clinical Pharmacology and Pharmacy, Department of Public Health, University of Southern Denmark, Odense, Denmark.,Department of Clinical Biochemistry and Clinical Pharmacology, Odense University Hospital, Odense, Denmark
| | | | | | - Henrik Toft Sørensen
- Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.,Department of Epidemiology and Population Health, Stanford University, Stanford, CA, USA
| | - Nanna Borup Johansen
- Department of Medical Evaluation and Biostatistics, Danish Medicines Agency, Copenhagen, Denmark
| | - Henrik Støvring
- Clinical Pharmacology and Pharmacy, Department of Public Health, University of Southern Denmark, Odense, Denmark.,Department of Public Health - Biostatistics, Aarhus University, Aarhus, Denmark
| | - Steffen Christensen
- Department of Anesthesia and Intensive Care Medicine, Aarhus University Hospital, Aarhus, Denmark
| | | | - Anders Husby
- Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark
| | | | - Jesper Kjær
- Data Analytics Center, Danish Medicines Agency, Copenhagen, Denmark
| | - Nikolai C Brun
- Department of Medical Evaluation and Biostatistics, Danish Medicines Agency, Copenhagen, Denmark
| |
Collapse
|
4
|
Kemp K, Brun NC, Quartarolo JP. Advanced analytics – translating registry science into regulatory actions. Expert Opin Drug Saf 2020; 19:533-535. [DOI: 10.1080/14740338.2020.1736555] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Affiliation(s)
- Kåre Kemp
- Pharmacovigilance and Medical Devices, Danish Medicines Agency, Copenhagen, Denmark
| | - Nikolai C. Brun
- Medical Evaluation and Biostatistics, Danish Medicines Agency, Copenhagen, Denmark
| | - Jens P. Quartarolo
- Pharmacovigilance and Medical Devices, Danish Medicines Agency, Copenhagen, Denmark
| |
Collapse
|
5
|
Cave A, Brun NC, Sweeney F, Rasi G, Senderovitz T. Big Data - How to Realize the Promise. Clin Pharmacol Ther 2020; 107:753-761. [PMID: 31846513 PMCID: PMC7158218 DOI: 10.1002/cpt.1736] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2019] [Accepted: 12/12/2019] [Indexed: 12/27/2022]
Abstract
The increasing volume and complexity of data now being captured across multiple settings and devices offers the opportunity to deliver a better characterization of diseases, treatments, and the performance of medicinal products in individual healthcare systems. Such data sources, commonly labeled as big data, are generally large, accumulating rapidly, and incorporate multiple data types and forms. Determining the acceptability of these data to support regulatory decisions demands an understanding of data provenance and quality in addition to confirming the validity of new approaches and methods for processing and analyzing these data. The Heads of Agencies and the European Medicines Agency Joint Big Data Taskforce was established to consider these issues from the regulatory perspective. This review reflects the thinking from its first phase and describes the big data landscape from a regulatory perspective and the challenges to be addressed in order that regulators can know when and how to have confidence in the evidence generated from big datasets.
Collapse
Affiliation(s)
- Alison Cave
- European Medicines Agency, Amsterdam, Netherlands
| | | | | | - Guido Rasi
- European Medicines Agency, Amsterdam, Netherlands
| | | | | |
Collapse
|
6
|
Plesner T, Arkenau HT, Lokhorst HM, Gimsing P, Krejcik J, Lemech CR, Minnema M, Lassen UN, Ahmadi T, Yeh H, Guckert M, Brun NC, Lisby S, Basse L, Palumbo A, Richardson PG. Safety and efficacy of daratumumab with lenalidomide and dexamethasone in relapsed or relapsed, refractory multiple myeloma. J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.15_suppl.8533] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | | | | | | | | | | | | | | | - Howard Yeh
- Janssen Research and Development, Raritan, NJ
| | | | | | | | | | | | | |
Collapse
|
7
|
Lokhorst HM, Laubach J, Nahi H, Plesner T, Gimsing P, Hansson M, Minnema M, Lassen UN, Krejcik J, Ahmadi T, Lisby S, Basse L, Brun NC, Richardson PG. Dose-dependent efficacy of daratumumab (DARA) as monotherapy in patients with relapsed or refractory multiple myeloma (RR MM). J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.15_suppl.8513] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | - Hareth Nahi
- Karolinska Universitetssjukhuset-Huddinge, Huddinge, Sweden
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Diringer MN, Skolnick BE, Mayer SA, Steiner T, Davis SM, Brun NC, Broderick JP. Thromboembolic events with recombinant activated factor VII in spontaneous intracerebral hemorrhage: results from the Factor Seven for Acute Hemorrhagic Stroke (FAST) trial. Stroke 2009; 41:48-53. [PMID: 19959538 DOI: 10.1161/strokeaha.109.561712] [Citation(s) in RCA: 98] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND AND PURPOSE Patients with intracerebral hemorrhage have a high risk of thromboembolic events (TEs) due to advanced age, hypertension, atherosclerosis, diabetes, and immobility. Use of recombinant activated factor VII (rFVIIa) could increase TEs in high-risk patients. Factor Seven for Acute Hemorrhagic Stroke (FAST) trial data were reviewed to define the frequency of and risk factors for TE with rFVIIa. METHODS Eight hundred forty-one patients presenting <3 hours after spontaneous intracerebral hemorrhage were randomized to 20 or 80 microg/kg of rFVIIa or placebo. Those with Glasgow Coma Scale score <5, planned early surgery, coagulopathy, or recent TE were excluded. Myocardial, cerebral, or venous TEs were subject to detailed reporting and expedited local review. Additionally, a blinded Data Monitoring Committee reviewed all electrocardiograms, centrally analyzed troponin I values, and CT scans. RESULTS There were 178 arterial and 47 venous TEs. Venous events were similar across groups. There were 49 (27%) arterial events in the placebo group, 47 (26%) in the 20-microg/kg group, and 82 (46%) in the 80 microg/kg group (P=0.04). Of the myocardial events, 38 were investigator-reported and 103 identified by the Data Monitoring Committee. They occurred in 17 (6.3%) placebo and 57 (9.9%) rFVIIa patients (P=0.09). Arterial TEs were associated with: receiving 80 microg/kg rFVIIa (OR=2.14; P=0.031), signs of cardiac or cerebral ischemia at presentation (OR=4.19; P=0.010), age (OR=1.14/5 years; P=0.0123), and prior use of antiplatelet agents (OR=1.83; P=0.035). Ischemic strokes possibly related to study drug occurred in 7, 5, and 8 patients in the placebo, 20 microg/kg, and 80-microg/kg groups, respectively. CONCLUSIONS Higher doses of rFVIIa in a high-risk population are associated with a small increased risk of what are usually minor cardiac events. Demonstration of the ability of rFVIIa to improve outcome in future studies should be driven by its effectiveness in slowing bleeding outweighting the risk of a small increase in arterial TEs.
Collapse
Affiliation(s)
- Michael N Diringer
- Department of Neurology, Box 8111, Washington University, 660 South Euclid Avenue, St Louis, MO 63110, USA.
| | | | | | | | | | | | | |
Collapse
|
9
|
Mayer SA, Davis SM, Skolnick BE, Brun NC, Begtrup K, Broderick JP, Diringer MN, Steiner T. Can a Subset of Intracerebral Hemorrhage Patients Benefit From Hemostatic Therapy With Recombinant Activated Factor VII? Stroke 2009; 40:833-40. [DOI: 10.1161/strokeaha.108.524470] [Citation(s) in RCA: 122] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background and Purpose—
In the Factor Seven for Acute Hemorrhagic Stroke (FAST) trial, 80 μg/kg of recombinant activated factor VII (rFVIIa) significantly reduced intracerebral hemorrhage (ICH) expansion when given within 4 hours of onset. However, in contrast to an earlier Phase 2b study, rFVIIa did not improve survival or functional outcome. In this exploratory analysis, we hypothesized that earlier treatment and exclusion of patients with a poor prognosis at baseline might enhance the benefit of rFVIIa treatment.
Methods—
Using the FAST data set, the impact of rFVIIa (80 μg/kg) on poor outcome at 3 months (modified Rankin Score of 5 or 6) was systematically evaluated within subgroups using clinically meaningful cut points in onset-to-treatment time, age, and baseline ICH and intraventricular hemorrhage volume. The effect of treatment on outcome was analyzed using logistic regression, and ICH volume was analyzed with linear mixed models.
Results—
A subgroup (n=160, 19% of the FAST population) was identified comprising patients ≤70 years with baseline ICH volume <60 mL, intraventricular hemorrhage volume <5 mL, and time from onset-to-treatment ≤2.5 hours. The adjusted ORs for poor outcome with rFVIIa treatment was 0.28 (95% CI, 0.08 to 1.06), whereas the reduction in ICH growth was almost doubled (7.3±3.2 versus 3.8±1.5 mL,
P
=0.02). The improved effect was confirmed in an analysis of similar Phase 2 patients.
Conclusions—
A prospective trial would be needed to determine whether younger patients with ICH without extensive bleeding at baseline can benefit from 80 μg/kg of rFVIIa given within 2.5 hours of symptom onset.
Collapse
Affiliation(s)
- Stephan A. Mayer
- From the Departments of Neurology and Neurosurgery (S.A.M.), Columbia University, New York, NY; the Department of Neurology (S.M.D.), Royal Melbourne Hospital and University of Melbourne, Melbourne, Australia; the Clinical, Medical and Regulatory Department (B.E.S.), Novo Nordisk, Princeton, NJ; Clinical Development (N.C.B., K.B.), Novo Nordisk A/S, Bagsværd, Denmark; the Department of Neurology (J.P.B.), University of Cincinnati, Cincinnati, Ohio; the Department of Neurology (M.N.D.), Washington
| | - Stephen M. Davis
- From the Departments of Neurology and Neurosurgery (S.A.M.), Columbia University, New York, NY; the Department of Neurology (S.M.D.), Royal Melbourne Hospital and University of Melbourne, Melbourne, Australia; the Clinical, Medical and Regulatory Department (B.E.S.), Novo Nordisk, Princeton, NJ; Clinical Development (N.C.B., K.B.), Novo Nordisk A/S, Bagsværd, Denmark; the Department of Neurology (J.P.B.), University of Cincinnati, Cincinnati, Ohio; the Department of Neurology (M.N.D.), Washington
| | - Brett E. Skolnick
- From the Departments of Neurology and Neurosurgery (S.A.M.), Columbia University, New York, NY; the Department of Neurology (S.M.D.), Royal Melbourne Hospital and University of Melbourne, Melbourne, Australia; the Clinical, Medical and Regulatory Department (B.E.S.), Novo Nordisk, Princeton, NJ; Clinical Development (N.C.B., K.B.), Novo Nordisk A/S, Bagsværd, Denmark; the Department of Neurology (J.P.B.), University of Cincinnati, Cincinnati, Ohio; the Department of Neurology (M.N.D.), Washington
| | - Nikolai C. Brun
- From the Departments of Neurology and Neurosurgery (S.A.M.), Columbia University, New York, NY; the Department of Neurology (S.M.D.), Royal Melbourne Hospital and University of Melbourne, Melbourne, Australia; the Clinical, Medical and Regulatory Department (B.E.S.), Novo Nordisk, Princeton, NJ; Clinical Development (N.C.B., K.B.), Novo Nordisk A/S, Bagsværd, Denmark; the Department of Neurology (J.P.B.), University of Cincinnati, Cincinnati, Ohio; the Department of Neurology (M.N.D.), Washington
| | - Kamilla Begtrup
- From the Departments of Neurology and Neurosurgery (S.A.M.), Columbia University, New York, NY; the Department of Neurology (S.M.D.), Royal Melbourne Hospital and University of Melbourne, Melbourne, Australia; the Clinical, Medical and Regulatory Department (B.E.S.), Novo Nordisk, Princeton, NJ; Clinical Development (N.C.B., K.B.), Novo Nordisk A/S, Bagsværd, Denmark; the Department of Neurology (J.P.B.), University of Cincinnati, Cincinnati, Ohio; the Department of Neurology (M.N.D.), Washington
| | - Joseph P. Broderick
- From the Departments of Neurology and Neurosurgery (S.A.M.), Columbia University, New York, NY; the Department of Neurology (S.M.D.), Royal Melbourne Hospital and University of Melbourne, Melbourne, Australia; the Clinical, Medical and Regulatory Department (B.E.S.), Novo Nordisk, Princeton, NJ; Clinical Development (N.C.B., K.B.), Novo Nordisk A/S, Bagsværd, Denmark; the Department of Neurology (J.P.B.), University of Cincinnati, Cincinnati, Ohio; the Department of Neurology (M.N.D.), Washington
| | - Michael N. Diringer
- From the Departments of Neurology and Neurosurgery (S.A.M.), Columbia University, New York, NY; the Department of Neurology (S.M.D.), Royal Melbourne Hospital and University of Melbourne, Melbourne, Australia; the Clinical, Medical and Regulatory Department (B.E.S.), Novo Nordisk, Princeton, NJ; Clinical Development (N.C.B., K.B.), Novo Nordisk A/S, Bagsværd, Denmark; the Department of Neurology (J.P.B.), University of Cincinnati, Cincinnati, Ohio; the Department of Neurology (M.N.D.), Washington
| | - Thorsten Steiner
- From the Departments of Neurology and Neurosurgery (S.A.M.), Columbia University, New York, NY; the Department of Neurology (S.M.D.), Royal Melbourne Hospital and University of Melbourne, Melbourne, Australia; the Clinical, Medical and Regulatory Department (B.E.S.), Novo Nordisk, Princeton, NJ; Clinical Development (N.C.B., K.B.), Novo Nordisk A/S, Bagsværd, Denmark; the Department of Neurology (J.P.B.), University of Cincinnati, Cincinnati, Ohio; the Department of Neurology (M.N.D.), Washington
| |
Collapse
|
10
|
Steiner T, Broderick J, Brun NC, Davis SM, Diringer MN, Mayer S, Skolnick BE. Timing Is Everything in Intracerebral Hemorrhage. Stroke 2008; 39:e117-8; author reply e119-20. [DOI: 10.1161/strokeaha.108.517979] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- Thorsten Steiner
- Department of Neurology, University of Heidelberg, Heidelberg, Germany
| | - Joseph Broderick
- Department of Neurology, The Neuroscience Institute, University of Cincinnati Medical Center, Cincinnati, Ohio, USA
| | | | - Stephen M. Davis
- Department of Neurology, Royal Melbourne Hospital/University of Melbourne, Parkville, Australia
| | - Michael N. Diringer
- Neurology/Neurosurgery Intensive Care Unit, Washington University School of Medicine, St Louis, Mo, USA
| | - Stephan Mayer
- Departments of Neurology and Neurosurgery, Columbia University College of Physicians and Surgeons, New York, NY, USA
| | | |
Collapse
|
11
|
Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, Skolnick BE, Steiner T. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2008; 358:2127-37. [PMID: 18480205 DOI: 10.1056/nejmoa0707534] [Citation(s) in RCA: 847] [Impact Index Per Article: 52.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
BACKGROUND Intracerebral hemorrhage is the least treatable form of stroke. We performed this phase 3 trial to confirm a previous study in which recombinant activated factor VII (rFVIIa) reduced growth of the hematoma and improved survival and functional outcomes. METHODS We randomly assigned 841 patients with intracerebral hemorrhage to receive placebo (268 patients), 20 microg of rFVIIa per kilogram of body weight (276 patients), or 80 microg of rFVIIa per kilogram (297 patients) within 4 hours after the onset of stroke. The primary end point was poor outcome, defined as severe disability or death according to the modified Rankin scale 90 days after the stroke. RESULTS Treatment with 80 microg of rFVIIa per kilogram resulted in a significant reduction in growth in volume of the hemorrhage. The mean estimated increase in volume of the intracerebral hemorrhage at 24 hours was 26% in the placebo group, as compared with 18% in the group receiving 20 microg of rFVIIa per kilogram (P=0.09) and 11% in the group receiving 80 microg (P<0.001). The growth in volume of intracerebral hemorrhage was reduced by 2.6 ml (95% confidence interval [CI], -0.3 to 5.5; P=0.08) in the group receiving 20 microg of rFVIIa per kilogram and by 3.8 ml (95% CI, 0.9 to 6.7; P=0.009) in the group receiving 80 microg, as compared with the placebo group. Despite this reduction in bleeding, there was no significant difference among the three groups in the proportion of patients with poor clinical outcome (24% in the placebo group, 26% in the group receiving 20 microg of rFVIIa per kilogram, and 29% in the group receiving 80 microg). The overall frequency of thromboembolic serious adverse events was similar in the three groups; however, arterial events were more frequent in the group receiving 80 microg of rFVIIa than in the placebo group (9% vs. 4%, P=0.04). CONCLUSIONS Hemostatic therapy with rFVIIa reduced growth of the hematoma but did not improve survival or functional outcome after intracerebral hemorrhage. (ClinicalTrials.gov number, NCT00127283 [ClinicalTrials.gov].).
Collapse
Affiliation(s)
- Stephan A Mayer
- Department of Neurology, Columbia University College of Physicians and Surgeons, New York, USA.
| | | | | | | | | | | | | | | |
Collapse
|
12
|
Diringer MN, Skolnick BE, Mayer SA, Steiner T, Davis SM, Brun NC, Broderick JP. Risk of Thromboembolic Events in Controlled Trials of rFVIIa in Spontaneous Intracerebral Hemorrhage. Stroke 2008; 39:850-6. [DOI: 10.1161/strokeaha.107.493601] [Citation(s) in RCA: 61] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- Michael N. Diringer
- From the Department of Neurology/Neurosurgery Intensive Care Unit (M.N.D.), Washington University School of Medicine, St Louis, Mo; Novo Nordisk Inc (B.E.S.), Princeton, NJ; the Departments of Neurology and Neurosurgery, Columbia University College of Physicians and Surgeons (S.A.M.), New York, NY; the Department of Neurology (T.S.), University of Heidelberg, Germany; the Department of Neurology (S.M.D.), Royal Melbourne Hospital/University of Melbourne, Parkville, Australia; Novo Nordisk, Bagsværd
| | - Brett E. Skolnick
- From the Department of Neurology/Neurosurgery Intensive Care Unit (M.N.D.), Washington University School of Medicine, St Louis, Mo; Novo Nordisk Inc (B.E.S.), Princeton, NJ; the Departments of Neurology and Neurosurgery, Columbia University College of Physicians and Surgeons (S.A.M.), New York, NY; the Department of Neurology (T.S.), University of Heidelberg, Germany; the Department of Neurology (S.M.D.), Royal Melbourne Hospital/University of Melbourne, Parkville, Australia; Novo Nordisk, Bagsværd
| | - Stephan A. Mayer
- From the Department of Neurology/Neurosurgery Intensive Care Unit (M.N.D.), Washington University School of Medicine, St Louis, Mo; Novo Nordisk Inc (B.E.S.), Princeton, NJ; the Departments of Neurology and Neurosurgery, Columbia University College of Physicians and Surgeons (S.A.M.), New York, NY; the Department of Neurology (T.S.), University of Heidelberg, Germany; the Department of Neurology (S.M.D.), Royal Melbourne Hospital/University of Melbourne, Parkville, Australia; Novo Nordisk, Bagsværd
| | - Thorsten Steiner
- From the Department of Neurology/Neurosurgery Intensive Care Unit (M.N.D.), Washington University School of Medicine, St Louis, Mo; Novo Nordisk Inc (B.E.S.), Princeton, NJ; the Departments of Neurology and Neurosurgery, Columbia University College of Physicians and Surgeons (S.A.M.), New York, NY; the Department of Neurology (T.S.), University of Heidelberg, Germany; the Department of Neurology (S.M.D.), Royal Melbourne Hospital/University of Melbourne, Parkville, Australia; Novo Nordisk, Bagsværd
| | - Stephen M. Davis
- From the Department of Neurology/Neurosurgery Intensive Care Unit (M.N.D.), Washington University School of Medicine, St Louis, Mo; Novo Nordisk Inc (B.E.S.), Princeton, NJ; the Departments of Neurology and Neurosurgery, Columbia University College of Physicians and Surgeons (S.A.M.), New York, NY; the Department of Neurology (T.S.), University of Heidelberg, Germany; the Department of Neurology (S.M.D.), Royal Melbourne Hospital/University of Melbourne, Parkville, Australia; Novo Nordisk, Bagsværd
| | - Nikolai C. Brun
- From the Department of Neurology/Neurosurgery Intensive Care Unit (M.N.D.), Washington University School of Medicine, St Louis, Mo; Novo Nordisk Inc (B.E.S.), Princeton, NJ; the Departments of Neurology and Neurosurgery, Columbia University College of Physicians and Surgeons (S.A.M.), New York, NY; the Department of Neurology (T.S.), University of Heidelberg, Germany; the Department of Neurology (S.M.D.), Royal Melbourne Hospital/University of Melbourne, Parkville, Australia; Novo Nordisk, Bagsværd
| | - Joseph P. Broderick
- From the Department of Neurology/Neurosurgery Intensive Care Unit (M.N.D.), Washington University School of Medicine, St Louis, Mo; Novo Nordisk Inc (B.E.S.), Princeton, NJ; the Departments of Neurology and Neurosurgery, Columbia University College of Physicians and Surgeons (S.A.M.), New York, NY; the Department of Neurology (T.S.), University of Heidelberg, Germany; the Department of Neurology (S.M.D.), Royal Melbourne Hospital/University of Melbourne, Parkville, Australia; Novo Nordisk, Bagsværd
| |
Collapse
|
13
|
Abstract
Recombinant activated coagulation factor VII (rFVIIa) was developed for the treatment of patients with hemophilia who have developed inhibitors against the factor they are missing. Hemophilia is a serious bleeding disorder and patients with hemophilia develop repeated spontaneous CNS, joint and muscle bleeding. Any trauma, even mild events, may cause life-threatening bleeding, and without treatment, these patients have a life expectancy of about 16 years. Thus, hemophilia can be regarded as a model of severe bleeding, and an agent capable of inducing hemostasis in severe hemophilia independent of the hemophilia proteins (FVIII or FIX) may also be effective in patients without hemophilia who experience serious bleeds. The availability of rFVIIa stimulated research on the role of FVII and tissue factor (TF) in the hemostatic process. As a result, a picture partly different from the one suggested by previous models has emerged. These previous models basically neglected the role of cells and cell membranes. The importance of platelets and platelet membrane phospholipids in hemostasis has been demonstrated, and the new concept of the hemostatic process, focusing on cell surfaces, has been outlined.
Collapse
|
14
|
Diringer MN, Ferran JM, Broderick J, Davis S, Mayer SA, Steiner T, Brun NC, Skolnick BE, Christensen MC. Impact of Recombinant Activated Factor VII on Health-Related Quality of Life after Intracerebral Hemorrhage. Cerebrovasc Dis 2007; 24:219-25. [PMID: 17630481 DOI: 10.1159/000104481] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2006] [Accepted: 03/01/2007] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND We recently demonstrated that recombinant activated factor VII (rFVIIa) given to patients presenting within 3 h of acute spontaneous intracerebral hemorrhage (ICH) reduces mortality (18% vs. 29%) and poor outcome (modified Rankin Scale, mRS, 4-6, 53 vs. 69%). This analysis was performed to determine the impact of rFVIIa on health-related quality of life (HRQoL) in those patients. METHODS In a prospective, randomized controlled trial, 399 patients (mean age, 66 years) received placebo, 40, 80 or 160 microg/kg of rFVIIa within 4 h of acute ICH. At 90 days, HRQoL was assessed with the EuroQoL (EQ-5D), a 5-dimensional measure of health which also includes the Visual Analogue Scale. Additionally, each level of the 90-day mRS was adjusted, using 4 different previously published utility values, to obtain a clearer picture of perceived HRQoL. RESULTS Among the 5 dimensions of EQ-5D, only mobility rating was significantly better for rFVIIa-treated patients (serious problems, 34 vs. 54%; p = 0.01). Yet, the utility value (scaled 1.0 = perfect health and 0.0 = dead) associated with the composite EQ-5D demonstrated significantly better HRQoL (0.48 vs. 0.36; p = 0.01). This was also true for the EQ-5D Visual Analogue Scale score (44 vs. 36; p = 0.04). Finally, all 4 algorithms for applying utility scores to the mRS indicated that rFVIIa was associated with significantly better perceived HRQoL (all p < 0.006). CONCLUSIONS Treatment with rFVIIa within 4 h of acute spontaneous ICH improves HRQoL.
Collapse
Affiliation(s)
- Michael N Diringer
- Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Abstract
BACKGROUND AND PURPOSE We report an exploratory analysis from a randomized study of recombinant activated factor VII (rFVIIa) in patients with intracerebral hemorrhage (ICH) examining potential factors associated with hemorrhage growth. METHODS We explored the relationship between 5 different measures of change in hemorrhage volume between baseline and 24-hour CTs (absolute and percent change in ICH volume, ICH growth-categoric [no growth if change <33% and <12.5 mL], absolute and percent change in ICH plus intraventricular hemorrhage [IVH] volume) and 31 demographic, clinical, imaging, historic, and baseline laboratory variables. Variables with a probability value of < or =0.10 were included in the final multivariable models. RESULTS Treatment with rFVIIa and a longer time-from-onset-to-baseline CT were related to a decrease in hemorrhage growth in all 5 models. ICH volume on baseline CT was consistently associated with ICH growth in the various models. Other variables significantly related to growth of ICH or ICH+IVH in at least 1 of the 5 models include serum glucose (increased levels associated with increased growth), body mass index (heavier people have less growth), prior use of antiplatelet agent (prior use associated with increased growth), serum cholesterol (higher level associated with less hemorrhage growth), and serum creatinine (higher level associated with more hemorrhage growth). CONCLUSIONS Our exploratory analyses confirm that treatment with rFVIIa limits ICH growth in subjects with spontaneous ICH who met the criteria for this study. Most hematoma growth occurs early after onset of ICH. Larger hematomas on the baseline CT were associated with increased absolute ICH growth. The relationship of other factors to hemorrhage growth warrants further study.
Collapse
Affiliation(s)
- Joseph P Broderick
- Department of Neurology, The Neuroscience Institute, University of Cincinnati Medical Center, Cincinnati, OH, USA.
| | | | | | | | | | | | | | | |
Collapse
|
16
|
Davis SM, Broderick J, Hennerici M, Brun NC, Diringer MN, Mayer SA, Begtrup K, Steiner T. Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage. Neurology 2006; 66:1175-81. [PMID: 16636233 DOI: 10.1212/01.wnl.0000208408.98482.99] [Citation(s) in RCA: 762] [Impact Index Per Article: 42.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
BACKGROUND Although volume of intracerebral hemorrhage (ICH) is a predictor of mortality, it is unknown whether subsequent hematoma growth further increases the risk of death or poor functional outcome. METHODS To determine if hematoma growth independently predicts poor outcome, the authors performed an individual meta-analysis of patients with spontaneous ICH who had CT within 3 hours of onset and 24-hour follow-up. Placebo patients were pooled from three trials investigating dosing, safety, and efficacy of rFVIIa (n = 115), and 103 patients from the Cincinnati study (total 218). Other baseline factors included age, gender, blood glucose, blood pressure, Glasgow Coma Score (GCS), intraventricular hemorrhage (IVH), and location. RESULTS Overall, 72.9% of patients exhibited some degree of hematoma growth. Percentage hematoma growth (hazard ratio [HR] 1.05 per 10% increase [95% CI: 1.03, 1.08; p < 0.0001]), initial ICH volume (HR 1.01 per mL [95% CI: 1.00, 1.02; p = 0.003]), GCS (HR 0.88 [95% CI: 0.81, 0.96; p = 0.003]), and IVH (HR 2.23 [95% CI: 1.25, 3.98; p = 0.007]) were all associated with increased mortality. Percentage growth (cumulative OR 0.84 [95% CI: 0.75, 0.92; p < 0.0001]), initial ICH volume (cumulative OR 0.94 [95% CI: 0.91, 0.97; p < 0.0001]), GCS (cumulative OR 1.46 [95% CI: 1.21, 1.82; p < 0.0001]), and age (cumulative OR 0.95 [95% CI: 0.92, 0.98; p = 0.0009]) predicted outcome modified Rankin Scale. Gender, location, blood glucose, and blood pressure did not predict outcomes. CONCLUSIONS Hematoma growth is an independent determinant of both mortality and functional outcome after intracerebral hemorrhage. Attenuation of growth is an important therapeutic strategy.
Collapse
Affiliation(s)
- S M Davis
- Department of Neurology, Royal Melbourne Hospital, University of Melbourne, Parkville, Australia.
| | | | | | | | | | | | | | | |
Collapse
|
17
|
Zimmerman RD, Maldjian JA, Brun NC, Horvath B, Skolnick BE. Radiologic estimation of hematoma volume in intracerebral hemorrhage trial by CT scan. AJNR Am J Neuroradiol 2006; 27:666-70. [PMID: 16552014 PMCID: PMC7976993] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/07/2023]
Abstract
BACKGROUND AND PURPOSE Therapeutic intervention during the early stages of an intracerebral hemorrhage (ICH) might have value in improving clinical outcomes. During the 73-site International Recombinant Activated Factor VII Intracerebral Hemorrhage Trial, CT techniques were used to monitor the change in hematoma volume in response to treatment. The use of CT imaging technology served 3 functions: to provide accurate measurements of the change in hematoma volume, intraventricular volume (IVH), and edema volume; to evaluate the use of CT scans as a predictor of patient outcomes; and to demonstrate that hematoma volume can serve as a surrogate marker for ICH clinical progression. METHODS The multicenter clinical trial received institutional review board approval and obtained informed consent from the patient or a legally acceptable representative (waived in a few cases of incapacity, according to local and national regulations). CT scans were used to quantify volumes of hemorrhage and to monitor evolution over a 72-hour period in patients with ICH treated with placebo or 40, 80, or 160 microg/kg of recombinant activated factor VII (rFVIIa). CT image data were transmitted digitally to an imaging laboratory and analyzed by 2 readers masked to patient and treatment data, by using Analyze software, a fully integrated toolkit for interactive display, processing, and measurement of biomedical image data. The use of this software enabled the evaluation of intraclass variability of CT scan interpretations. RESULTS Interpretations of ICH and IVH volumes of CT scans in patients treated in this study showed minimal intraclass variability. Variability was greatest for interpretations of edema volume. CONCLUSION These CT assessments of lesions could have value in future early hemostatic interventions in ICH patients.
Collapse
Affiliation(s)
- R D Zimmerman
- Weill Medical College of Cornell University, Ithaca, NY, USA
| | | | | | | | | |
Collapse
|
18
|
Mayer SA, Brun NC, Broderick J, Davis SM, Diringer MN, Skolnick BE, Steiner T. Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage: US Phase IIA Trial. Neurocrit Care 2006; 4:206-14. [PMID: 16757825 DOI: 10.1385/ncc:4:3:206] [Citation(s) in RCA: 68] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/1999] [Revised: 11/30/1999] [Accepted: 11/30/1999] [Indexed: 11/11/2022]
Abstract
BACKGROUND AND PURPOSE Ultra-early hemostatic therapy may improve outcome after intracerebral hemorrhage (ICH) by preventing rebleeding and hematoma expansion. We conducted this trial to evaluate the safety of activated recombinant factor VII (rFVIIa; NovoSeven) for preventing early hematoma growth in acute ICH. METHODS In this multicenter, randomized, double-blind, placebo-controlled, dose-escalation trial, 40 patients diagnosed with ICH by computed tomography within 3 hours of onset were treated with placebo or 5, 20, 40, or 80 microg/kg of rFVIIa ( n = 8 per group). Patients with any history of thromboembolic or vaso-occlusive disease were excluded. The primary endpoint was the frequency of adverse events (AEs). RESULTS Mean age was 65 years (range 34 - 91) and the median admission Glasgow Coma Scale score was 14.5 (range 6 to 15). Mean ICH volume was 17 +/- 19 mL; nearly three-quarters were located in the basal ganglia ( n = 29). The mean interval from onset to treatment was 178 +/- 41 minutes. Thirty-three patients experienced 186 AEs, which occurred with similar frequency in the five groups. There were 10 thromboembolic AEs, including one case of deep vein thrombosis (20 microg g/kg group); one case of cerebral infarction (placebo); two cases of pulmonary embolism (20 and 40 microg g/kg groups); and six instances of ischemic ECG changes or cardiac enzyme elevation (placebo [ n = 2], 20 microg g/kg [ n = 1], 40 microg g/kg [ n = 1], and 80 microg g/kg [ n = 2] groups). No consumption coagulopathy or dose-related increase in edema-to-ICH volume ratio occurred. CONCLUSIONS Ultra-early rFVIIa treatment for ICH was associated with a reasonable safety profile in this preliminary study across a wide range of dosages. Further research is warranted to investigate the safety and potential efficacy of rFVIIa for minimizing ICH growth.
Collapse
Affiliation(s)
- Stephan A Mayer
- Department of Neurology, Columbia University College of Physicians & Surgeons, New York, NY, USA.
| | | | | | | | | | | | | |
Collapse
|
19
|
Diringer MN, Davalos A, Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Skolnick BE, Steiner T. Effects of Recombinant Activated Factor VII on Perilesional Edema in Patients with Acute Intracerebral Hemorrhage. Neurosurgery 2005. [DOI: 10.1093/neurosurgery/57.2.395a] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
20
|
Abstract
BACKGROUND Intracerebral hemorrhage is the least treatable form of stroke and is associated with high mortality. Among patients who undergo computed tomography (CT) within three hours after the onset of intracerebral hemorrhage, one third have an increase in the volume of the hematoma related to subsequent bleeding. We sought to determine whether recombinant activated factor VII (rFVIIa) can reduce hematoma growth after intracerebral hemorrhage. METHODS We randomly assigned 399 patients with intracerebral hemorrhage diagnosed by CT within three hours after onset to receive placebo (96 patients) or 40 microg of rFVIIa per kilogram of body weight (108 patients), 80 microg per kilogram (92 patients), or 160 microg per kilogram (103 patients) within one hour after the baseline scan. The primary outcome measure was the percent change in the volume of the intracerebral hemorrhage at 24 hours. Clinical outcomes were assessed at 90 days. RESULTS Hematoma volume increased more in the placebo group than in the rFVIIa groups. The mean increase was 29 percent in the placebo group, as compared with 16 percent, 14 percent, and 11 percent in the groups given 40 microg, 80 microg, and 160 microg of rFVIIa per kilogram, respectively (P=0.01 for the comparison of the three rFVIIa groups with the placebo group). Growth in the volume of intracerebral hemorrhage was reduced by 3.3 ml, 4.5 ml, and 5.8 ml in the three treatment groups, as compared with that in the placebo group (P=0.01). Sixty-nine percent of placebo-treated patients died or were severely disabled (as defined by a modified Rankin Scale score of 4 to 6), as compared with 55 percent, 49 percent, and 54 percent of the patients who were given 40, 80, and 160 microg of rFVIIa, respectively (P=0.004 for the comparison of the three rFVIIa groups with the placebo group). Mortality at 90 days was 29 percent for patients who received placebo, as compared with 18 percent in the three rFVIIa groups combined (P=0.02). Serious thromboembolic adverse events, mainly myocardial or cerebral infarction, occurred in 7 percent of rFVIIa-treated patients, as compared with 2 percent of those given placebo (P=0.12). CONCLUSIONS Treatment with rFVIIa within four hours after the onset of intracerebral hemorrhage limits the growth of the hematoma, reduces mortality, and improves functional outcomes at 90 days, despite a small increase in the frequency of thromboembolic adverse events.
Collapse
Affiliation(s)
- Stephan A Mayer
- Department of Neurology, Columbia University College of Physicians and Surgeons, New York, USA.
| | | | | | | | | | | | | | | |
Collapse
|
21
|
Abstract
Background and Purpose—
Hematoma growth occurs in 38% of intracerebral hemorrhage (ICH) patients scanned by computed tomography (CT) within 3 hours of onset. Activated recombinant factor VII (rFVIIa) promotes hemostasis at sites of vascular injury and may minimize hematoma growth after ICH.
Methods—
In this randomized, double-blind, placebo-controlled, dose-escalation trial, 48 subjects with ICH diagnosed within 3 hours of onset were treated with placebo (n=12) or rFVIIa (10, 20, 40, 80, 120, or 160 μg/kg; n=6 per group). The primary endpoint was the frequency of adverse events (AEs). Safety assessments included serial electrocardiography (ECG), troponin I and coagulation testing, lower extremity Doppler ultrasonography, and calculation of edema:ICH volume ratios.
Results—
Mean age was 61 years (range, 30 to 93) and 57% were male. At admission, mean National Institutes of Health Stroke Scale (NIHSS) score was 14 (range, 1 to 26), median Glasgow Coma Scale score was 14 (range, 6 to 15), and mean ICH volume was 21 mL (range, 1 to 151). Mean time from onset to treatment was 181 minutes (range, 120 to 265). Twelve serious AEs occurred, including 5 deaths (mortality 11%). Six AEs were considered possibly treatment-related, including rash, vomiting, fever, ECG T-wave inversion, and 2 cases of deep vein thrombosis (placebo and 20-μg/kg groups). No myocardial ischemia, consumption coagulopathy, or dose-related increase in edema:ICH volume occurred.
Conclusion—
This small phase II trial evaluated a wide range of rFVIIa doses in acute ICH and raised no major safety concerns. Larger studies are justified to determine whether rFVIIa can safely and effectively limit ICH growth.
Collapse
Affiliation(s)
- Stephan A Mayer
- Department of Neurology, Columbia University College of Physicians and Surgeons, New York, NY, USA.
| | | | | | | | | | | | | |
Collapse
|
22
|
Feet BA, Gilland E, Groenendaal F, Brun NC, Hellström-Westas L, Hagberg H, Saugstad OD. Cerebral excitatory amino acids and Na+,K+-ATPase activity during resuscitation of severely hypoxic newborn piglets. Acta Paediatr 1998; 87:889-95. [PMID: 9736239 DOI: 10.1080/080352598750013699] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
We tested the hypothesis that early brain recovery in hypoxic newborn piglets is improved by resuscitating with an O2 supply close to the minimum level required by the newborn piglet brain. Severely hypoxic 2-5-d-old anaesthetized piglets were randomly divided into three resuscitation groups: hypoxaemic (n = 8), 21% O2 (n = 8), and 100% O2 groups (n = 8). The hypoxaemic group was mechanically ventilated with 12-18% O2 adjusted to achieve a cerebral venous O2 saturation of 17-23% (baseline; 45 +/- 1%, mean +/- SEM). During the 2h resuscitation period, extracellular aspartate and glutamate concentrations in the cerebral striatum were higher during hypoxaemic resuscitation (p = 0.044 and p = 0.055, respectively) than during resuscitation with 21% O2 or 100% O2, suggesting an unfavourable accumulation of potent excitotoxins during hypoxaemic resuscitation. The cell membrane Na+,K+-ATPase activity of cerebral cortical tissue after 2 h resuscitation was similar in the three groups (p = 0.30). In conclusion, hypoxaemic resuscitation did not normalize early cerebral metabolic recovery as efficiently as resuscitation with 21% O2 or 100% O2. Resuscitation with 21% O2 was as efficient as resuscitation with 100% O2 in this newborn piglet hypoxia model.
Collapse
Affiliation(s)
- B A Feet
- Department of Paediatric Research and Institute for Surgical Research, National Hospital, Oslo, Norway
| | | | | | | | | | | | | |
Collapse
|
23
|
Feet BA, Brun NC, Hellström-Westas L, Svenningsen NW, Greisen G, Saugstad OD. Early cerebral metabolic and electrophysiological recovery during controlled hypoxemic resuscitation in piglets. J Appl Physiol (1985) 1998; 84:1208-16. [PMID: 9516186 DOI: 10.1152/jappl.1998.84.4.1208] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
We tested the hypothesis that controlled hypoxemic resuscitation improves early cerebral metabolic and electrophysiological recovery in hypoxic newborn piglets. Severely hypoxic anesthetized piglets were randomly divided into three resuscitation groups: hypoxemic, 21% O2, and 100% O2 groups (8 in each group). The hypoxemic group was mechanically ventilated with 12-18% O2 adjusted to achieve a cerebral venous O2 saturation of 17-23% (baseline; 45 +/- 1%). Base excess (BE) reached -22 +/- 1 mM at the end of hypoxia. During a 2-h resuscitation period, no significant differences in time to recovery of electroencephalography (EEG), quality of EEG at recovery, or extracellular hypoxanthine concentrations in the cerebral cortex and striatum were found among the groups. BE and plasma hypoxanthine, however, normalized significantly more slowly during controlled hypoxemic resuscitation than during resuscitation with 21 or 100% O2. We conclude that early brain recovery during controlled hypoxemic resuscitation was as efficient as, but not superior to, recovery during resuscitation with 21 or 100% O2. The systemic metabolic recovery from hypoxia, however, was delayed during controlled hypoxemic resuscitation.
Collapse
Affiliation(s)
- B A Feet
- Department of Pediatric Research and Institute for Surgical Research, The National Hospital, N-0027 Oslo, Norway.
| | | | | | | | | | | |
Collapse
|
24
|
Brun NC, Moen A, Børch K, Saugstad OD, Greisen G. Near-infrared monitoring of cerebral tissue oxygen saturation and blood volume in newborn piglets. Am J Physiol 1997; 273:H682-6. [PMID: 9277484 DOI: 10.1152/ajpheart.1997.273.2.h682] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Near-infrared spectrophotometry (NIRS) potentially provides a tool for noninvasive tissue oxygenation and blood volume monitoring. Cerebral monitoring could be useful in the prevention of hypoxic ischemic brain injury in newborns. This study sought to validate such NIRS measurements in normoventilated, hypocapnic, and hypoxemic states in the brain of newborn piglets vs. arterial (SaO2) and sagittal sinus blood hemoglobin saturation (SssO2) and blood volume measurements with 99mTc-labeled erythrocytes. NIRS measurements of cerebral blood volume (CBV) were performed with both oxyhemoglobin and indocyanine green as tracers, and changes in CBV were monitored by following the change in the concentration of total hemoglobin (i.e., oxyhemoglobin + deoxyhemoglobin). NIRS CBV measurements did not correlate well with the radioactive measurements. NIRS measurements of oxygenation, however, correlated well with a weighted mean value of SaO2 and SssO2 (r = 0.90; P < 0.0001). Multiple linear regression of the oxygenation index (i.e., oxyhemoglobin - deoxyhemoglobin) on SaO2 and SssO2 suggested that NIRS sees hemoglobin in tissue in a venous-to-arterial ratio of 2:1. Therefore, in this study, NIRS reliably monitored changes in cerebral tissue oxygenation but not in CBV.
Collapse
Affiliation(s)
- N C Brun
- Department of Neonatology, National University Hospital, Rigshospitalet, Copenhagen, Denmark
| | | | | | | | | |
Collapse
|
25
|
Skov L, Brun NC, Greisen G. Neonatal intensive care: an obvious, yet difficult area for cerebral near-infrared spectroscopy. J Biomed Opt 1997; 2:7-14. [PMID: 23014817 DOI: 10.1117/12.260021] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
|
26
|
Abstract
Near-infrared spectrophotometry can be used to measure cerebral concentrations of oxyhemoglobin and deoxyhemoglobin. This has been applied to developing methods for quantifying cerebral blood volume (CBV), which is relevant for the investigation of the pathogenesis of brain injury in newborn infants as well as older infants. This study investigates the internal consistency between measurements of CBV using two methods: the oxygen method, which is able to determine absolute values of CBV, and the total Hb method, which can detect changes in CBV only. Cerebral blood flow (CBF) was also measured. Fifteen premature infants were examined. Due to practical problems, in only eight of these was a minimum of two CBF and two CBV values obtained both before and after a change in arterial PCO2 of at least 0.5 kPa. A significant difference between the CBV-CO2 reactivity found by the two methods was demonstrated: 0.89 mL/100 g/kPa (95% confidence interval = 0.63-1.26) for the oxygen method and 0.22 mL/100 g/kPa (95% confidence interval = 0.08-0.36) for the total Hb method. This finding is substantiated by the absolute values of CBV [mean value = 3.7 mL/100 g (SD = 1.1)], CBF [mean value = 11.3 mL/100 g/min (SD = 5.9)], and CBF reactivity [59 +/- 9% (SEM)]. All the values correspond well with previous findings, although the CBV reactivity determined by the oxygen method has not been reported previously. The reason for the discrepancy between the two methods is unclear, but induced changes in the scattering properties of the brain would give rise to errors influencing the total Hb method rather than the oxygen method.
Collapse
Affiliation(s)
- N C Brun
- Department of Neonatology, Rigshospitalet, Copenhagen, Denmark
| | | |
Collapse
|